DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma

Inclusion Criteria

• •Histologically confirmed high-grade serous or endometrioid carcinoma of the ovary, peritoneum or fallopian tube.
• •Without disease progression during preceding platinum-based chemotherapy
• •Platinum-sensitive patients defined as Platinum-Free Interval of more than 6 months between the end of the last cycle of platinum-based chemotherapy and radiologic evidence of progression.
• •First relapse identified by the criteria above up to 28 days prior to study randomization
• •Eastern Cooperative Oncology Group (ECOG) performance status 0-1
• •Known BRCA (breast cancer susceptibility gene) mutation status before randomization
• •Patient is intended to be treated with bevacizumab, best supportive care (BSC) only or PARPi